{
    "nctId": "NCT04674852",
    "briefTitle": "Mayo Designed Soft Tissue Ultrasound-Detectable Marker",
    "officialTitle": "A Mayo-Designed Nonmetallic, Ultrasound-Detectable Marker for Metastatic Axillary Lymph Nodes in Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasm Female, Ultrasound Therapy; Complications",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DEVICE_FEASIBILITY",
    "enrollmentCount": 8,
    "primaryOutcomeMeasure": "Ultrasound detectability",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient 18 years or older with breast cancer and biopsy-proven malignant involvement of an axillary lymph node\n* Surgical management involves preoperative radioactive seed localization of a previously identified positive axillary lymph node\n* Surgery will be performed by Dr. James Jakub at Mayo Clinic Rochester, MN\n* Radioactive seed localization of an axillary lymph node.\n* No contraception is necessary or required.\n* English speaking\n\nExclusion Criteria:\n\n* Scheduled for only radioactive seed localizations in the breast (as opposed to axilla)\n* Are pregnant; although the twinkling marker is made of material widely used in orthopedic procedures, and hence, has an excellent safety profile, the investigators want to exclude the population of pregnant patients in this phase 0 clinical trial.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}